DE69634955D1 - Tripeptidylpeptidase-inhibitoren - Google Patents

Tripeptidylpeptidase-inhibitoren

Info

Publication number
DE69634955D1
DE69634955D1 DE69634955T DE69634955T DE69634955D1 DE 69634955 D1 DE69634955 D1 DE 69634955D1 DE 69634955 T DE69634955 T DE 69634955T DE 69634955 T DE69634955 T DE 69634955T DE 69634955 D1 DE69634955 D1 DE 69634955D1
Authority
DE
Germany
Prior art keywords
tripeptidylpeptidase
inhibitors
formulawherein
cholecystokinin
hydrates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69634955T
Other languages
English (en)
Other versions
DE69634955T2 (de
Inventor
Christiane Rose
Froylan Vargas
Pierre Bourgeat
Jean-Charles Schwartz
Beaumont Bishop
Babarao Bambal
Robin Ganellin
Bertrand Leblond
N Moore
Suzanne Chan
Zhao Lihua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioprojet SC
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Bioprojet SC
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet SC, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Bioprojet SC
Application granted granted Critical
Publication of DE69634955D1 publication Critical patent/DE69634955D1/de
Publication of DE69634955T2 publication Critical patent/DE69634955T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
DE69634955T 1995-05-09 1996-05-09 Tripeptidylpeptidase-inhibitoren Expired - Fee Related DE69634955T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9505489 1995-05-09
FR9505489A FR2733995B1 (fr) 1995-05-09 1995-05-09 Inhibiteurs de l'inactivation de neuropeptides endogenes notamment la cholecystokinine, leurs procedes de preparation leur utilisation comme medicaments et procede de criblage de medicaments
PCT/FR1996/000700 WO1996035805A2 (fr) 1995-05-09 1996-05-09 Inhibiteurs de tripeptidylpeptidases

Publications (2)

Publication Number Publication Date
DE69634955D1 true DE69634955D1 (de) 2005-08-25
DE69634955T2 DE69634955T2 (de) 2006-05-24

Family

ID=9478806

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634955T Expired - Fee Related DE69634955T2 (de) 1995-05-09 1996-05-09 Tripeptidylpeptidase-inhibitoren

Country Status (11)

Country Link
US (2) US6403561B1 (de)
EP (1) EP0828851B1 (de)
JP (1) JPH11510684A (de)
AT (1) ATE299948T1 (de)
CA (1) CA2221035A1 (de)
DE (1) DE69634955T2 (de)
DK (1) DK0828851T3 (de)
ES (1) ES2244969T3 (de)
FR (1) FR2733995B1 (de)
PT (1) PT828851E (de)
WO (1) WO1996035805A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733995B1 (fr) * 1995-05-09 1997-07-25 Inst Nat Sante Rech Med Inhibiteurs de l'inactivation de neuropeptides endogenes notamment la cholecystokinine, leurs procedes de preparation leur utilisation comme medicaments et procede de criblage de medicaments
CA2315703C (en) * 1997-12-23 2008-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tripeptidyl peptidase inhibitors
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
AU2001252922A1 (en) * 2000-04-19 2001-11-07 Eli Lilly And Company Azide cyclization-based synthesis and intermediates for spla2 inhibitors
CA2422617C (en) 2000-10-30 2011-07-12 Janssen Pharmaceutica N.V. Tripeptidyl peptidase inhibitors
CA2464214C (en) 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US20030165574A1 (en) * 2002-03-01 2003-09-04 Ward Loren Spencer Compositions and methods for treatment of body weight conditions
US20040097422A1 (en) * 2002-06-14 2004-05-20 Karl Munger Methods of use for tripeptidyl peptidase II inhibitors as anticancer agents
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
EP2906535B1 (de) * 2012-10-11 2018-08-08 F.Hoffmann-La Roche Ag Indoline

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH626872A5 (de) * 1976-06-21 1981-12-15 Hoffmann La Roche
CH627735A5 (de) * 1976-06-25 1982-01-29 Hoffmann La Roche Verfahren zur herstellung von dipeptidderivaten.
HU180925B (en) * 1979-06-28 1983-05-30 Richter Gedeon Vegyeszet Process for producing tripeptide-amides trh-analogues,effectives on the central nerve systhem
CS226907B1 (en) * 1981-08-07 1984-04-16 Kasafirek Evzen Alkylamides of carboxyalkanoylpeptides
AT389517B (de) * 1987-10-08 1989-12-27 Hoechst Ag Chromophore peptide, verfahren zu ihrer herstellung und ihre verwendung zum nachweis der peptidylglycin-alpha-amidierenden monooxygenase
US5159060A (en) * 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
EP1050540B1 (de) * 1991-10-22 2006-12-27 New England Medical Center Hospitals, Inc. Inhibitoren der Dipeptidyl-Aminopeptidase vom Typ IV
FR2733995B1 (fr) * 1995-05-09 1997-07-25 Inst Nat Sante Rech Med Inhibiteurs de l'inactivation de neuropeptides endogenes notamment la cholecystokinine, leurs procedes de preparation leur utilisation comme medicaments et procede de criblage de medicaments

Also Published As

Publication number Publication date
US20030027743A1 (en) 2003-02-06
DE69634955T2 (de) 2006-05-24
DK0828851T3 (da) 2005-10-24
ES2244969T3 (es) 2005-12-16
FR2733995A1 (fr) 1996-11-15
EP0828851A2 (de) 1998-03-18
PT828851E (pt) 2005-11-30
FR2733995B1 (fr) 1997-07-25
EP0828851B1 (de) 2005-07-20
US6403561B1 (en) 2002-06-11
JPH11510684A (ja) 1999-09-21
ATE299948T1 (de) 2005-08-15
WO1996035805A2 (fr) 1996-11-14
CA2221035A1 (fr) 1996-11-14
WO1996035805A3 (fr) 1997-01-30

Similar Documents

Publication Publication Date Title
ATE250576T1 (de) Substituierte pyrrolylverbindungen zur behandlung von entzündungen
ES2116436T5 (es) Carbamatos y agentes fitosanitarios que contienen estos.
DE69325249D1 (de) Behandlung von unterirdischen Lagerstätten mit Zellulose- und Guarderivaten
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
SE9103612D0 (sv) New peptide derivatives
PL316658A1 (en) Novel application of serotonin antagonists
NO975245L (no) Heterocykluser som inhibitorer av leukosyttadhesjon og VLA-4-antagonister
NO942994D0 (no) Aminoacetylmercaptoacetylamidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
ATE299948T1 (de) Tripeptidylpeptidase-inhibitoren
BG102918A (en) Biphenylsulphanomide inhibitors of the matrix metalloproteinase
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
MX9708452A (es) Inhibidores de sialidasa bacteriana y metodos para fabricar y usar la misma.
DK1000034T3 (da) Substituerede 6-alkylphenanthridiner
TR199801665T2 (xx) Makular �demin engellenmesi i�in karbonik anhidraz inhibit�rlerinin kullan�m�.
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
DE69628360D1 (de) Azepinonverbindungen zur Anwendung bei der Hemmung von ACE und NEP
FI946156A0 (fi) Luun uudistumiseen vaikuttavien kasvutekijöiden kohdistettu anto
GB2324091A (en) Metalloproteinase inhibitors
DE59709922D1 (de) Pflaster zur transdermalen anwendung von pergolid
ES2285735T3 (es) Modelo molecular para inhibidores de vla-4.
ES2060405T3 (es) Derivado de la melatonina que tiene actividad terapeutica en dermatologia.
FI954367A0 (fi) Substituoitujen alkyylinitraattien käyttö patologisesti kohonneen intraokulaarisen paineen hoitamiseksi
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
AR005866A1 (es) Composicion farmaceutica antioxidante
EA199900174A1 (ru) Способ лечения биполярного расстройства

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee